Long-term Study of ORX750 for Narcolepsy and Hypersomnia
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- Centessa Pharmaceuticals (UK) Limited · Industry
This trial is looking for individuals diagnosed with narcolepsy or idiopathic hypersomnia who have completed a prior study. Participants will take ORX750 and help researchers understand its long-term safety and effectiveness.
You may be able to join if
- I have been diagnosed with narcolepsy type 1 or type 2 or idiopathic hypersomnia.
- I completed the full treatment period in the previous study.
You may not be able to join if
- I have developed a new disease or disorder that prevents me from continuing.
- I cannot stop taking medications that are not allowed for this study.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Loading trial locations…